1 / 12

Rimonabant: New therapeutic option for managing cardiometabolic risk

Explore how rimonabant offers a new approach to managing obesity and metabolic syndrome, impacting cardiovascular disease risk. Learn about the endocannabinoid system, clinical trials, and potential benefits and safety considerations.

hermang
Download Presentation

Rimonabant: New therapeutic option for managing cardiometabolic risk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rimonabant:New therapeutic option for managing cardiometabolic risk

  2. Unmet needs in obesity and the metabolic syndrome • Obesity, metabolic syndrome, and diabetes have reached epidemic proportions • Increased prevalence of these conditions is projected to have a major impact on CV disease and associated costs of care • Even modest weight loss (5%–10%) can reduce cardiometabolic risk factors • Current behavioral and dietary approaches to weight loss have limited success • New approaches to weight loss are urgently needed Gelfand EV, Cannon CP. J Am Coll Cardiol. 2006;47:1919-26.NIH Expert Panel. Obes Res. 1998;6(suppl 2):51S-209S.

  3. Endocannabinoid system (ECS): Overview Endocannabinoid ligands • Produced on demand • Act locally • Inactivated rapidly • Bind to transmembrane G-protein receptors,principally inhibiting neurotransmitter release Cannabinoid receptor type 1 (CB1) Cannabinoid receptor type 1 (CB1) Cannabinoid receptor type 2 (CB2) Most widespread CB receptor (brain, spinal cord; peripheral nervous system, organs, tissues) Immune cells Gelfand EV, Cannon CP. J Am Coll Cardiol. 2006;47:1919-26.Pagotto U et al. Ann Med. 2005;37:270-5.

  4. Implications of CB1 receptor activation Central nervous system Peripheral tissue Liver GI tract Adipose tissue Skeletal muscle Hypothalamus Limbic system Appetite Motivation to eat/smoke Lipogenesis Altered glucose metabolism Gelfand EV, Cannon CP. J Am Coll Cardiol. 2006;47:1919-26.Pagotto U et al. Ann Med. 2005;37:270-5.

  5. Overview of rimonabant clinical trial programs for the treatment of multiple cardiometabolic risk factors • Rimonabant In Obesity (RIO) • RIO-Europe • RIO-Lipids • RIO-North America (NA) • RIO-Diabetes • Studies with Rimonabant and Tobacco Use (STRATUS) • STRATUS-United States • STRATUS-Europe • STRATUS-Worldwide • Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant—The Intravascular Ultrasound Study (STRADIVARIUS) Gelfand EV, Cannon CP. J Am Coll Cardiol. 2006;47:1919-26.

  6. Rimonabant In Obesity (RIO) program Després J-P et al. N Engl J Med. 2005.Pi-Sunyer FX et al. JAMA. 2006. Gelfand EV et al. J Am Coll Cardiol. 2006. *Hypertension and/or dyslipidemia †RIO-NA: Rimonabant patients re-randomized at 1 year to placebo or continued rimonabant

  7. RIO clinical trial program: Efficacy overview RIO-Europe, RIO-Lipids, RIO-NA; Placebo-corrected change from baseline at 1 year Van Gaal LF et al. Lancet. 2005. Després J-P et al. N Engl J Med. 2005.Pi-Sunyer FX et al. JAMA. 2006. *P ≤ 0.002 vs placebo †P = 0.02 vs placebo

  8. Significant decrease in metabolic syndrome 60 52.9 50 42.2 40 34.8 * Patients * 30 25.8 (%) * 21.2 19.6 20 10 0 RIO-Europe RIO-Lipids RIO-NA Baseline 1 year Rimonabant 20 mg ↓51% ↓39% ↓54% (n = 599) (n = 346) (n = 1222) Van Gaal LF et al. Lancet. 2005.Després J-P et al. N Engl J Med. 2005.Pi-Sunyer FX et al. JAMA. 2006. ATP III criteria *P < 0.001 vs placebo

  9. RIO clinical trial program: Safety and tolerability overview • Most common drug-related adverse event was mild nausea • Rimonabant 5 mg (5.1%–7.2%); 20 mg (11.2%–12.9%) • Adverse event-related discontinuation rate was similar or slightly higher vs placebo • Rimonabant 5 mg (8.3%–9.4%); 20 mg (12.8%–15.0%); placebo (7.0%–9.2%) • Changes in anxiety and depression scores (HAD scale) were similar across treatment and placebo groups Van Gaal LF et al. Lancet. 2005.Després J-P et al. N Engl J Med. 2005.Pi-Sunyer FX et al. JAMA. 2006. HAD = Hospital Anxiety and Depression

  10. Rimonabant: No significant effect on mood HAD scale: Scores at 1 year Van Gaal LF et al. Lancet. 2005. Després J-P et al. N Engl J Med. 2005.Pi-Sunyer FX et al. JAMA. 2006.

  11. Rimonabant: RIO program summary • Over 1 year, rimonabant 20 mg combined with diet demonstrated: • Significant decreases in weight and waist circumference • Weight loss: 14.0–15.3 lbs absolute change, 10.4–12.0 lbs placebo-corrected change • Favorable changes in cardiometabolic risk factor profile Van Gaal LF et al. Lancet. 2005;365:1389-97. Després J-P et al. N Engl J Med. 2005;353:2121-34.Pi-Sunyer FX et al. JAMA. 2006;295:761-75.

  12. Rimonabant: Therapeutic potential • Cannabinoid receptor blockade is a novel approach to treatment of cardiometabolic risk factors • Any degree of weight loss can impact metabolic syndrome and diabetes, ultimately reducing CV risk • Moderate weight loss encourages continued health-promoting behaviors and adherence to medical therapy Gelfand EV, Cannon CP. J Am Coll Cardiol. 2006;47:1919-26.

More Related